The prospectively collected data from the Canadian Melanoma Research Network (CMRN) includes patients with BRAF-mutated melanoma who were initiated on either immunotherapy or targeted therapy for first-line treatment, followed by the other for second-line treatment. This evidence concerns the gene BRAF and melanoma.